Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D; community with critical information on the tools, technologies, and trends that drive the biotech industry.
Issue link: http://gen.epubxp.com/i/83770
Corporate Capabilities ADVERTORIAL Fujifilm Diosynth Biotechnologies F ujifilm Diosynth Biotechnologies is an industry-leading biologics contract manufacturing organization with loca- tions in Research Triangle Park, North Carolina, and Billingham, U.K. The company was formed in April 2011 following the acquisi- tion of the Merck BioManufacturing Network, which consisted of the former Diosynth Biotech- nology and Avecia Biologics businesses. As Fujfilm Diosynth Biotechnologies we have over 25 years' combined experience in the devel- opment and manufacture of recombinant pro- teins, vaccines, monoclonal antibodies, expressed in a wide array of microbial, mammalian, and insect systems. Markets Served We serve biopharmaceutical clients of all siz- es, worldwide, including virtual, big, and small biotechnology companies and large pharmaceu- tical companies from around the globe. Expertise in the development, refinement,and technology transfer of preclinical through com- mercial cGMP manufacturing processes has been repeatedly demonstrated. Scale-up, valida- tion, and regulatory services support customers in North America, Europe, Canada, Australia, and Japan. Our goal is to increase the value of our customers' pipeline and products. We help our customers succeed by developing processes efficiently, rapidly, and cost-effectively from pre- Fujifilm Diosynth Biotechnologies 101 J. Morris Commons Lane Morrisville, NC 27560 Phone 866.762.6259 Website www.fujifilmdiosynth.com Date Founded 2011 (as Fujifilm Diosynth Biotechnologies) More than 15 years as Diosynth Biotechnology & Avecia Biologics Number of Employees > 800 clinical development to market supply. Capabilities As a full-service contract manufacturer, we can meet your needs at every stage of the prod- uct lifecycle. We offer an extensive breadth of process-development capabilities from cell- line and strain development, using proprietary pAVEway™ and CHO cell line systems, to process development, analytical development, clinical and commercial manufacturing. We have recently announced increased capacity for mammalian cell culture production at both sites, which are FDA-approved for the production of commercial products. Our capabilities include, but are not lim- ited to: expertise in producing products from a wide range of cell types including CHO, NS0, SP2/0, hybridoma, E. coli, Pichia pastoris, S. cerevisiae, and Baculo- virus; batch, fed-batch and single-use bioreactor production technologies are employed at volumes from 15 L to 5,000 L; production of recombi- nant proteins/peptides products for therapeutic and vaccine applications from mammalian and microbial expression sys- tems; expert operator of multi-product facilities and a long track record of efficient execution of cGMP manufacturing campaigns. Experience solutions and learn more about how we can assist your development and man- ufacturing programs, please contact us. Q 72 | October 1, 2012 | genengnews.com | Genetic Engineering & Biotechnology News